Abstract Rationale & Objective The approved therapeutic indication for immune checkpoint
inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the …

Background Immune checkpoint inhibitors (ICPi) are a novel and promising anti-cancer
therapy. There are limited data on the incidence, risk factors and outcomes of acute kidney …

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has
emerged as an important toxicity among patients with cancer. Methods We collected data on …

Abstract Background/objectives Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors
therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event …

Background Despite increasing recognition of the importance of immune checkpoint
inhibitor–associated AKI, data on this complication of immunotherapy are sparse. Methods …

Introduction Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers.
Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are
associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI …

Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients.
These humanized monoclonal antibodies against various immune checkpoints (receptors …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …